Allena Pharmaceuticals Inc
NASDAQ:ALNA
Income Statement
Earnings Waterfall
Allena Pharmaceuticals Inc
Revenue
|
0
USD
|
Operating Expenses
|
-41m
USD
|
Operating Income
|
-41m
USD
|
Other Expenses
|
-2.3m
USD
|
Net Income
|
-43.3m
USD
|
Income Statement
Allena Pharmaceuticals Inc
Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||||||||||||||
Operating Expenses |
(22)
|
(20)
|
(21)
|
(23)
|
(27)
|
(32)
|
(36)
|
(40)
|
(42)
|
(46)
|
(47)
|
(43)
|
(39)
|
(33)
|
(32)
|
(36)
|
(43)
|
(48)
|
(48)
|
(48)
|
(41)
|
|
Selling, General & Administrative |
(4)
|
(5)
|
(5)
|
(6)
|
(8)
|
(9)
|
(9)
|
(10)
|
(10)
|
(10)
|
(10)
|
(10)
|
(10)
|
(11)
|
(12)
|
(12)
|
(13)
|
(14)
|
(13)
|
(13)
|
(12)
|
|
Research & Development |
(18)
|
(16)
|
(16)
|
(17)
|
(20)
|
(24)
|
(26)
|
(30)
|
(32)
|
(36)
|
(37)
|
(33)
|
(28)
|
(22)
|
(20)
|
(24)
|
(30)
|
(34)
|
(35)
|
(35)
|
(29)
|
|
Operating Income |
(22)
N/A
|
(20)
+8%
|
(21)
-3%
|
(23)
-12%
|
(27)
-16%
|
(32)
-20%
|
(36)
-10%
|
(40)
-12%
|
(42)
-7%
|
(46)
-9%
|
(47)
-2%
|
(43)
+7%
|
(39)
+11%
|
(33)
+14%
|
(32)
+4%
|
(36)
-12%
|
(43)
-20%
|
(48)
-10%
|
(48)
0%
|
(48)
0%
|
(41)
+14%
|
|
Pre-Tax Income | ||||||||||||||||||||||
Interest Income Expense |
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Other Income |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
|
Pre-Tax Income |
(23)
N/A
|
(21)
+6%
|
(22)
-2%
|
(24)
-10%
|
(28)
-17%
|
(33)
-17%
|
(36)
-9%
|
(39)
-10%
|
(42)
-7%
|
(46)
-9%
|
(47)
-4%
|
(44)
+8%
|
(39)
+10%
|
(34)
+13%
|
(33)
+3%
|
(37)
-12%
|
(44)
-19%
|
(49)
-11%
|
(49)
0%
|
(49)
0%
|
(43)
+11%
|
|
Net Income | ||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(23)
|
(21)
|
(22)
|
(24)
|
(28)
|
(33)
|
(36)
|
(39)
|
(42)
|
(46)
|
(47)
|
(44)
|
(39)
|
(34)
|
(33)
|
(37)
|
(44)
|
(49)
|
(49)
|
(49)
|
(43)
|
|
Net Income (Common) |
(23)
N/A
|
(21)
+6%
|
(22)
-2%
|
(24)
-10%
|
(28)
-17%
|
(33)
-17%
|
(36)
-9%
|
(39)
-10%
|
(42)
-7%
|
(46)
-9%
|
(47)
-4%
|
(44)
+8%
|
(39)
+10%
|
(34)
+13%
|
(33)
+3%
|
(37)
-12%
|
(44)
-19%
|
(49)
-11%
|
(49)
0%
|
(49)
0%
|
(43)
+11%
|
|
EPS (Diluted) |
-1.1
N/A
|
-1.03
+6%
|
-1.05
-2%
|
-1.15
-10%
|
-1.34
-17%
|
-1.58
-18%
|
-1.72
-9%
|
-1.88
-9%
|
-2
-6%
|
-1.94
+3%
|
-2.01
-4%
|
-1.76
+12%
|
-1.46
+17%
|
-0.94
+36%
|
-0.78
+17%
|
-0.67
+14%
|
-0.76
-13%
|
-0.63
+17%
|
-0.59
+6%
|
-0.55
+7%
|
-0.43
+22%
|